Sun Pharma signs $55m manufacturing deal for investigational psoriasis drug

India’s biggest pharma firm has signed a $55 million long-term manufacturing deal with Korea’s Samsung BioLogics for Tildrakizumab, an investigational IL-23p19 inhibitor currently being assessed for efficacy in treating moderate to severe plaque psoriasis.

"The agreement was entered into by Sun Pharma's wholly-owned subsidiary and Samsung BioLogics," the two companies said in a joint statement. As part the deal, Samsung BioLogics will offer its manufacturing expertise and infrastructure to produce products in the Tildrakizumab pipeline.

"Samsung BioLogics is pleased to join hands with Sun Pharma and is looking forward to delivering best-in-class manufacturing services with global quality standards," TH Kim, Samsung BioLogics President and CEO, commented: "Our collaboration with Sun Pharma is an important milestone for Samsung as it is a testament of our ability to provide reliable supply through its GMP-certified manufacturing facility to pharmaceutical companies, which aim to expand their global market."  

Tildrakizumab has been accepted for review by both the FDA and EMA, and is currently waiting assessment.

Matt Fellows